STAR Molecule to Restore GCase Activity Showing Early Potential

STAR Molecule to Restore GCase Activity Showing Early Potential

312421

STAR Molecule to Restore GCase Activity Showing Early Potential

An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits in animal models of the disease. “We are working diligently to advance this breakthrough compound to the clinic and bring it one step closer to meeting the currently unaddressed needs of patients with this debilitating disease,” Eric Richman, CEO of Gain Therapeutics, which is developing the therapy, said in a press release. Results of preclinical tests…

You must be logged in to read/download the full post.